The 340B program has evolved significantly since its passage, but there are still important changes needed, like clarifying the target patient population. The complicated rebate system for payers and drug manufacturers is also a consequence that should be addressed, said Neil Minkoff, MD, chief medical officer of EmpiraMed.
The 340B program has evolved significantly since its passage, but there are still important changes needed, like clarifying the target patient population. The complicated rebate system for payers and drug manufacturers is also a consequence that should be addressed, said Neil Minkoff, MD, chief medical officer of EmpiraMed.
Transcript (slightly modified)
How has the 340B program evolved since it was enacted?
There have been a number of important changes, and there are a number of things that haven’t changed that might have to be assessed. Probably the things that have evolved the most are the massive expansion of the 340B program through new definitions, so more providers and more types of pharmacies can enter them, and more hospitals and more clinical entities realizing that there’s benefit to them for working through 340B programs.
One of the things that’s still vague and hasn’t evolved is the clear definition of which patients should and shouldn’t be in the 340B program, and how drugs can or cannot be specified for them.
How has the 340B program evolved to have unintended consequences?
I think the biggest one from the payer point of view is the rebate situation, where plans who are keeping careful track of which drugs are used in specialty and which drugs they have rebates on are submitting rebates to the manufacturers and getting back, sometimes, a quarter of them X-ed out, because they had already provided 340B discount pricing, and so the manufacturer isn’t going to do both.
From the manufacturer’s point of view, I think the risk is double discounting: places where, for whatever reason, but mostly lack of transparency in how the program is implemented, they may be paying double discounts.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More